The pharmacology of leishmaniasis

General Pharmacology

Volumn 30, Issue 4, 1998, Pages 435-443

  Balana Fouce R ^a   Reguera, R M ^a   Cubria J C ^a   Ordonez D ^a  

^a Pharmacol Toxicol (INTOXCAL) U   (Spain)

Author keywords

Chemotherapy; Leishmania spp.; Leishmaniasis; Pharmacology

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALLOPURINOL; ALLOPURINOL RIBOSIDE; AMPHOTERICIN B; ANTILEISHMANIAL AGENT; DIBROMPROPAMIDINE; DIMINAZENE; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; PAROMOMYCIN; PENTAMIDINE; PENTAMIDINE ISETHIONATE; PROPAMIDINE; STIBOGLUCONATE SODIUM; STILBAMIDINE;

BIOCHEMISTRY; CHEMOTHERAPY; DNA BINDING; DRUG DESIGN; DRUG EFFICACY; HOST PARASITE INTERACTION; HUMAN; LEISHMANIASIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTOZOON; RECURRENCE RISK; REVIEW; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS; WORLD HEALTH ORGANIZATION;

ALLOPURINOL; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; DRUG DESIGN; HUMANS; ITRACONAZOLE; KETOCONAZOLE; LEISHMANIA; LEISHMANIASIS; PAROMOMYCIN; WORLD HEALTH ORGANIZATION;

EID: 0032053990     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(97)00268-1     Document Type: Review

References (70)

1. Abahusein A., Larbi E. B., al Khawajah A., al-Gindan Y., Jain S. Evaluation of topical ketoconazole in cutaneous leishmaniasis. East Afr. Med. J. 69:1992;14-17.
2. Albanese G., Giorgetti P., Santagostino L., Crippa D., Sala G. Cutaneous leishmaniasis. treatment with itraconazole Arch. Dermatol. 125:1989;1540-1542.
3. Alvar J., Gutierrez-Solar B., Molina R., López-Vélez R., García-Camacho A., Martínez P., Laguna F., Cercenado E., Galmes A. Prevalence of Leishmania infantum among AIDS patients. Lancet. 339:1992;1427.
4. Anonymous Leishmania/HIV coinfection. Weekly Epidemiol. Rec. 72:1997;49-56.
5. Balaña-Fouce R., Ordóñez D., Alunda J. M. Putrescine transport system in Leishmania infantum promastigotes. Mol. Biochem. Parasitol. 35:1989;43-50.
6. Balaña-Fouce R., Escribano M. I., Alunda J. M. Leishmania infantum. polyamine levels and biosynthesis during the growth of promastigotes Int. J. Biochem. 23:1991;1213-1217.
7. Basselin M., Lawrence F., Robert-Gero M. Pentamidine uptake in Leishmania donovani and Leishmania amazonensis promastigotes and axenic amastigotes. Biochem. J. 315:1996;631-634.
8. Bell C. A., Hall J. E., Kyle D. E., Grogl M., Ohemeng K. A., Allen M. A., Tidwell R. R. Structure-activity relationships of analogs of pentamidine against Plasmodium falciparum and Leishmania mexicana amazonensis. Antimicrob. Agents Chemother. 34:1990;449-461.
9. Ben-Salah A., Zakraoui H., Zaatour A., Ftaiti A., Zaafouri B., Garraoui A., Olliaro P. L., Dellagi K., Ben Ismail R. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am. J. Med. Trop. Hyg. 53:1995;162-166.
10. Berger B. J., Fairlamb A. H. Interactions between immunity and chemotherapy in the treatment of the trypanosomiases and leishmaniases. Parasitology. 105:1992;S71-S78.
11. Berger B. J., Naiman N. A., Hall J. E., Peggins J., Brewer T. G., Tidwell R. R. Primary and secondary metabolism of pentamidine in rats. Antimicrob. Agents Chemother. 36:1992;1825-1831.
12. Berman J. D. Chemotherapy for leishmaniasis. biochemical mechanisms, clinical efficacy, and future strategies Rev. Infect. Dis. 10:1988;560-586.
13. Berman J. D., Ksionski G., Chapman W. L., Waits V. B., Hanson W. L. Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 36:1992;1978-1980.
14. Bernard E., Quaranta J. F., Durant J., Le Fichoux Y., Dellamonica P. Visceral leishmaniasis resistant to conventional treatments. value of amphotericin B Pathol. Biol. 41:1993;817-819.
15. Calonge M., Bayoumi A. E., Cubría J. C., Balaña-Fouce R., Ordóñez D. Effects of cationic diamidines on polyamine metabolism in the trypanosomatid Crithidia fasciculata. Life Sci. 59:1996;PL191-PL197. . a.
16. Calonge M., Johnson R., Cubría J. C., Balaña-Fouce R., Ordóñez D. Effects of cationic diamidines on polyamine content and uptake on Leishmania infantum in vitro cultures. Biochem. Pharmac. 52:1996;835-841. . b.
17. Chunge C. N., Owate J., Pamba H. O., Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans. R. Soc. Trop. Med. Hyg. 79:1990;715-718.
18. Conte J. E. Jr. Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis. J. Infect. Dis. 163:1991;169-175.
19. Cook G. C. Leishmaniasis. some recent developments in chemotherapy J. Antimicrob. Chemother. 31:1993;327-330.
20. Davidson R. N., Croft S. L., Scott A., Maini M., Moody A. H., Bryceson A. D. M. Liposomal amphotericin B in drug resistant visceral leishmaniasis. Lancet. 337:1991;1061-1062.
21. Desjeux P. Leishmaniasis, public health aspects and control. Clin. Dermatol. 14:1996;417-423.
22. Dogra J., Aneja N., Lal B. B., Mishra S. N. Cutaneous leishmaniasis in India. clinical experience with itraconazole (R51 211 Janssen) Int. J. Dermatol. 29:1990;661-662.
23. Dykstra C. C., Tidwell R. R. Inhibition of topoisomerases from Pneumocystis carinii by aromatic dicationic molecules. J. Protozool. 38:1991;78S-81S.
24. el-On J., Jacobs G. P., Weinrauch L. Topical chemotherapy of cutaneous leishmaniasis. Parasitol. Today. 4:1988;76-81.
25. Fairlamb A. H., Cerami A. Metabolism and function of trypanothione in the kinetoplastida. Ann. Rev. Microbiol. 46:1992;695-729.
26. Fairlamb A. H., Henderson G. B., Cerami A. Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proc. Natl. Acad. Sci. USA. 86:1989;2607-2611.
27. Feurestein B. G., Williams L. D., Basu H. S., Marton L. J. Implications and concepts of polyamine-nucleic acid interactions. J. Cell. Biochem. 46:1991;37-47.
28. Gangeux J. P., Sulahian A., Garin Y. J. F., Farinotti R., Derouin F. Therapy of visceral leishamaniasis due to Leishmania infantum. experimental assessment of efficacy of AmBisome Antimicrob. Agents Chemother. 40:1996;1214-1218.
29. Ghoda L., Wang C. C., Coffino P. Ornithine decarboxylase of African trypanosomes. Biochem. Soc. Trans. 18:1990;1493-1495.
30. Glew R. H., Saha A. K., Das S., Remaley A. Biochemistry of Leishmania species. Microbiol. Rev. 52:1988;412-432.
31. Goa K. L., Campoli-Richards D. M. Pentamidine isethionate. a review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia Drugs. 33:1987;242-258.
32. Goihman-Yahr M. American mucocutaneous leishmaniasis. Dermatol. Clin. 12:1994;703-712.
33. Gorgolas M. A., Miles M. A. Visceral leishmaniasis and AIDS. Nature. 373:1994;734.
34. Gradoni L., Bryceson A., Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull. W. H. O. 73:1995;191-197.
35. Grogl M., Thomason T. N., Franke A. D. Drug resistance in leishmaniasis. its application in systemic chemotherapy of cutaneous and mucocutaneous disease Am. J. Trop. Med. Hyg. 47:1992;117-126.
36. Halim M. A., Alfurayh O., Kalin M. E., Dammas S., al-Eisa A., Damanhouri G. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in a renal transplant recipient after the occurrence of pancreatitis due to stibogluconate. Clin. Infect. Dis. 16:1993;397-399.
37. Hay R. J. Liposomal amphotericin B, AmBisome. J. Infect. 28:1994;35-43.
38. Hepburn N. C., Tidman M. J., Hunter J. A. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 88:1994;700-703.
39. Herwaldt B. L., Berman J. D. Recommendations of treating leishmaniasis with sodium stibogluconate (pentostam) and review of pertinent clinical studies. Am. J. Trop. Med. Hyg. 46:1992;296-306.
40. Johnson R., Cubría J. C., Reguera M. R., Balaña-Fouce R. and Ordóñez D. The interaction of cationic diamidines with Leishmania infantum DNA. Biol. Chem. Hoppe Seyler (in press).
41. Kandpal M., Balaña-Fouce R., Pal A., Guru P. Y., Tekwani B. L. Kinetics and molecular characterization of arginine transport by Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 71:1995;193-201.
42. Laguna F., López-Vélez R., Soriano V., Montilla P., Alvar J., González-Lahoz J. M. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV. J. Infect. 28:1994;255-259.
43. Marr J. J. Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis. J. Lab. Clin. Med. 118:1991;111-119.
44. Martínez S., Marr J. J. Allopurinol in the treatment of American cutaneous leishmaniasis. N. Engl. J. Med. 326:1992;741-744.
45. Mishra M., Biswas U. K., Jha A. M., Khan A. B. Amphotericin versus sodium stibogluconate in first line treatment of Indian kala-azar. Lancet. 344:1994;1599-1600.
46. Momeni A. Z., Amninjavaheri M. Treatment of recurrent cutaneous Leishmaniasis. Int. J. Dermatol. 34:1995;129-133.
47. Moss J. T., Wilson J. P. Current treatment recommendations for leishmaniasis. Ann. Pharmacother. 26:1992;1452-1455.
48. Murray H. W., Hariprashad J., Fichtl R. E. Treatment of experimental visceral leishmaniasis in a T-cell deficient host. response to amphotericin B and pentamidine Antimicrob. Agents Chemother. 37:1993;1504-1505.
49. Navin T. R., Arana B. A., Arana F. E., Berman J. D., Chajon J. F. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J. Infect. Dis. 165:1992;528-534.
50. Norton S. A., Frankenburg S., Klaus S. N. Cutaneous leishmaniasis acquired during military service in the Middle East. Arch. Dermatol. 128:1992;83-87.
51. Nyakundi P. M., Wasunna K. M., Rashid J. R., Gachihi G. S., Mbugua J., Kirigi G., Muttunga J. Is one year follow-up justified in kala-azar posttreatment? East Afr. Med. J. 71:1994;453-459.
52. Nyakundi P. M., Rashid J. R., Wasunna K. M., Were J. B., Muigai R., Kirigi G., Mbugua J. Problems in the treatment of kala-azar. case report East Afr. Med. J. 72:1995;406-408.
53. Olliaro P. L., Bryceson A. D. M. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol. Today. 9:1993;323-328.
54. Pegg A. E. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res. 48:1988;759-774.
55. Rashid J. R., Wasunna K. M., Gachichi G. S., Nyakundi P. M., Mbugua J., Kirigi G. The efficacy and safety of ketoconazole in visceral leishmaniasis. East Afr. Med. J. 71:1994;392-395.
56. Reguera M. R., Balaña-Fouce R., Cubría J. C., Alvarez-Bujidos M. L., Ordóñez D. Putrescine uptake inhibition by aromatic diamidines in Leishmania infantum promastigotes. Biochem Pharmac. 47:1994;1859-1866.
57. Ribera E., Cucurull E., Ocaña I., Vallespi T., Gasser I., Juste C. Visceral leishmaniasis in patients with HIV infection. Enferm. Infecc. Microbiol. Clin. 13:1995;73-79.
58. Ribera E., Ocaña I., de Otero J., Cortés E., Gasser I., Pahissa A. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am. J. Med. 100:1996;496-501.
59. Saenz R. E., Paz H., Berman J. D. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am. J. Med. 89:1990;147-155.
60. Seaman J., Boer C., Wilkinson R., de Jong J., de Wilde E., Sondorp E., Davidson R. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin. Infect. Dis. 21:1995;188-193.
61. Sen D., Crothers D. M. Influence of DNA-binding drugs on chromatin condensation. Biochemistry. 25:1986;1503-1509.
62. Snyder R. D. Polyamine depletion is associated with altered chromatin structure in HeLa cells. Biochem. J. 260:1989;697-704.
63. Soto-Mancipe J., Grogl M., Berman J. D. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin. Infect. Dis. 16:1993;417-425.
64. Soto-Mancipe J., Hernández N., Mejía H., Grogl M., Berman J. D. Successful treatment of New World cutaneous leishmanaisis with a combination of topical paromomycin/methylbenzetonium chloride and injectable meglumine antimoniate. Clin. Infect. Dis. 20:1995;47-51.
65. Thakur C. P., Kumar M., Pandey A. K. Comparison of regimes of treatment of antimony-resistant kala-azar patients. a randomized study Am. J. Trop. Med. Hyg. 45:1991;435-441.
66. Van-Voorhis W. C. Therapy and prophylaxis of systemic protozoan infections. Drugs. 40:1990;176-202.
67. Vannier-Santos M. A., Urbina J. A., Martiny A., Neves A., de Souza W. Alterations induced by the antifungal compounds ketoconazole and terbinafine in Leishmania. J. Eukaryot. Microbiol. 42:1995;337-346.
68. Vidal-Puig A. J., Muñoz-Torres M., Jódar-Gimeno E., García-Calvente C. J., Lardelli P., Ruiz-Requena M. E., Escobar-Jiménez F. Ketoconazole therapy. hormonal and clinical effects in non-tumoral hyperandrogenism Eur. J. Endocrinol. 130:1994;333-338.
69. Vöhringer H. F., Arasteh K. Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia. Clin. Pharmacokinet. 24:1993;388-412.
70. Vöhringer H. F., Arasteh K., Hardtmann E., Hornscheidt M. Pharmakologische Untersuchungen mit Pentamidin-Aerosol bei HIV-Patienten. Med. Klin. 85:1990;248-250.